secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0001599298-24-000128
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit reports ivonescimab beats Keytruda in Phase 3 NSCLC trial; PFS HR=0.51 p<0.0001
--------------------------------------------------------------------------------

- Ivonescimab vs pembrolizumab in 1L PD-L1+ advanced NSCLC: mPFS 11.14 vs 5.82 months (HR 0.51, p<0.0001).
- ORR 50.0% vs 38.5%, DCR 89.9% vs 70.5%. OS not yet mature; safety manageable.
- Subgroup benefit consistent: PD-L1 TPS≥50% HR 0.46; squamous HR 0.48; non-squamous HR 0.54.
- Phase II perioperative AK112-205 in resectable NSCLC: MPR 71.8% (cohort 2), pCR 43.6% with ivonescimab+chemo.
- Additional Phase II data in breast, colorectal, head & neck cancers released at ESMO; conference call Sep 9.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000128/0001599298-24-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929824000128/smmt-20240908.htm
  HTML page:      https://secwatch.observer/filing/0001599298-24-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer